Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

News SummaryMost relevantAll newsSector news 

St. Jude Medical, Inc. : St Jude To Stop Selling Another Version Of Defibrillator Wires

share with twitter share with LinkedIn share with facebook
share via e-mail
04/04/2012 | 09:48am EST

St. Jude Medical Inc. (STJ) will stop selling another version of its defibrillator wires in an effort to head off potential problems like those the medical-device maker is currently battling with its Riata and Riata ST wires.

The Riata defibrillator wires, called leads, are no longer on the market but are still implanted in thousands of patients in the U.S. In a medical journal last month, prominent cardiologist Robert G. Hauser wrote that the cables are responsible for at least 20 deaths.

Wednesday, the company said it will cease selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart. Roughly 171,000 QuickSite and QuickFlex leads have been sold worldwide.

The decision comes as St. Jude has confirmed 39 cases of the metal wires wearing through their silicone covering, leading to an incidence rate of 2.3 in every 10,000 leads. Still, it stressed that its decision to stop selling the wires is a proactive one.

"It is important to note, however, that the overall safety and reliability of QuickSite and QuickFlex leads continues to be comparable to currently available CRT leads from other manufacturers," the company wrote.

The wire leads connect life-saving medical devices, which are placed under the skin in the shoulder area, to the heart and delivers a jolt that restores proper rhythm. Because of the constant pounding motion of the heart, the thin leads can be damaged.

Shares closed Tuesday at $43.80 and were inactive in premarket trading. The stock is up roughly 36% from lows hit late last year when the Food and Drug Administration termed the Riata defibrillator issues as a Class I recall, which applies to grave dangers like chance of death.

   -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ST. JUDE MEDICAL, INC.
05:13a ST JUDE MEDICAL : STJ) Gets CE Mark for Proclaim SCS System Conditional Labeling
05:13a ST JUDE MEDICAL : Receives CE Mark Approval for Full Body MR Conditional Labelin..
12/08 ST JUDE MEDICAL : Receives CE Mark Approval for Full Body MR Conditional Labelin..
12/07 ST JUDE MEDICAL : Assigned Patent
12/06 ST JUDE MEDICAL : ++ Suspicious death of woman with defibrillator ++
11/28 Global Radiofrequency Ablation Market - Angiodynamics, Boston Scientific, Cov..
11/24 ST JUDE MEDICAL : Assigned Patent
11/22 ST JUDE MEDICAL : Patent Issued for Method for Loading a Self-Expanding Collapsi..
11/22 ST JUDE MEDICAL : Patent Issued for Methods and Apparatus for Controlling the In..
11/22 ST JUDE MEDICAL : HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for P..
More news
Sector news : Medical Devices & Implants
12/07 MEDTRONIC : China says fines Medtronic local unit 118.5 million yuan for price f..
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue -- 2nd Update
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Medical Devices & Implants
News from SeekingAlpha
12/08 Abbott Vs. Alere, Or Kramer Vs. Kramer
12/08 St. Jude's Proclaim Elite SCS System receives CE Mark for full-body MRI claim
12/06 The Most And Least Loved Stocks In The S&P 500
11/28 5 Dividends That Make The Difference
11/23 Blackberry Plans To Shake Up Medtech Cybersecurity
Financials ($)
Sales 2016 6 044 M
EBIT 2016 1 510 M
Net income 2016 898 M
Debt 2016 4 713 M
Yield 2016 1,46%
P/E ratio 2016 25,34
P/E ratio 2017 20,09
EV / Sales 2016 4,56x
EV / Sales 2017 4,17x
Capitalization 22 829 M
More Financials
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 20
Average target price 82,0 $
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Michael T. Rousseau President, Chief Executive Officer & Director
Daniel J. Starks Executive Chairman
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ST. JUDE MEDICAL, INC.29.35%22 829
SMITH & NEPHEW PLC-6.46%12 480
GLAUKOS CORP35.93%1 126
More Results